Thalidomide suppresses melanoma growth by activating natural killer cells in mice

Oncology Reports

Volumn 16, Issue 6, 2006, Pages 1231-1236

  Kawamata, Ai ^a   Ito, Daisuke ^a   Odani, Takeshi ^a   Isobe, Tomohide ^a   Iwase, Masayasu ^a   Hatori, Masashi ^a   Nagumo, Masao ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

B16F1 melanoma; IL 12; IL 18; IP 10; Mouse; NK cells; Perforin; Thalidomide

Indexed keywords

ACTIN; ALPHA CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 12; MEMBRANE PROTEIN; PERFORIN; PORE FORMING CYTOTOXIC PROTEIN; THALIDOMIDE;

ANIMAL; ARTICLE; C57BL MOUSE; CANCER TRANSPLANTATION; CELL CYCLE; DRUG EFFECT; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MELANOMA; METABOLISM; MOUSE; NATURAL KILLER CELL; NEUTROPHIL CHEMOTAXIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ACTINS; ANIMALS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CHEMOKINES, CXC; CHEMOTAXIS, LEUKOCYTE; GENE EXPRESSION; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-1; INTERLEUKIN-12; KILLER CELLS, NATURAL; MELANOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PORE FORMING CYTOTOXIC PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THALIDOMIDE;

EID: 39049178372     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.6.1231     Document Type: Article

References (39)

1. Marriott JB, Muller G and Dalgleish AG: Thalidomide as an emerging immunotherapeutic agent. Immunol Today 20: 538-554, 1999.
2. Raje N and Anderson KC: Thalidomide: a revival story. N Engl J Med 341: 1606-1609. 1999.
3. Hales B: Thalidomide on the comeback trail. Nat Med 5: 489-490, 1999.
4. D'Amato RJ, Loughnan MS, Flynn E and Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994. (Pubitemid 24139577)
5. Raje N and Anderson KC: Thalidomide and immunomodulatory drugs as cancer therapy. Curr Opin Oncol 14: 635-640, 2002. (Pubitemid 35387374)
6. Duong DJ, Spigel GT, Moxley RT and Gaspari AA: American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol 135: 1079-1087, 1999. (Pubitemid 29430499)
7. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE and Gore ME: Continuous low dose thalidomide: a phase ll study in advanced melanoma, renal cell, ovarian, and breast cancer. Br J Cancer 82: 812-817, 2000. (Pubitemid 30085231)
8. Sampaio T, Sarno EN, Galally R, Cohn ZA and Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173: 699-703, 1991.
9. Meierhofer C, Dunzendorfer S and Wiedermann CJ: Theoretical basis for the activity of thalidomide. Biodrugs 15: 681-703, 2001. (Pubitemid 33078988)
10. Haslett PA, Corral LG, Albert M and Kaplan G: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8 + subset. J Exp Med 187: 1885-1892, 1998. (Pubitemid 28262451)
11. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI and Kaplan G: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 163: 380-386, 1999. (Pubitemid 29295864)
12. Favre-Felix N, Martin M, Maraskovsky E, Fronmentin A, Moutet M, Solary E, Martin F and Bonnotte B: Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function. Int J Cancer 86: 827-834, 2000. (Pubitemid 30350198)
13. Boehm U, Klamp T, Groot M and Howard JC: Cellular responses to interferon-γ. Annu Rev Immunol 15: 749-795, 1997.
14. Xing Z, Zganiacz A, Wang J and Sharma SK: Enhanced protection against fatal mycobacterial infection in SCID beige mice by reshaping innate immunity with IFN-γ transgene. J Immunol 167: 375-383, 2001. (Pubitemid 32567802)
15. Ito D, Back TC, Shakhov AN, Wiltrout RH and Nedospasov SA: Mice with a targeted mutation in lymphotoxin-alpha exhibit enhanced tumor growth and metastasis: impaired NK cell development and recruitment. J Immunol 163: 2809-2815, 1999. (Pubitemid 29399209)
16. Fogler WE, Volker K, McCormick KL, Watanabe M, Ortaldo JR and Wiltrout RH: NK cell infiltration into lung, liver, and subcutaneous B16 melanoma is mediated by VCAM-1/VLA-4 interaction. J Immunol 156: 4707-4714, 1996. (Pubitemid 26174454)
17. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI and Anderson KC: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98: 210-216, 2001.
18. Fidler IJ: Biological behavior of malignant melanoma cells correlated to their survival in vivo . Cancer Res 35: 218-224, 1975.
19. Fleischmann CM, Wu TY and Fleischmann WR Jr: B16 melanoma cells exposed in vitro to long-term IFN-alpha treatment (B16 alpha cells) as activators of tumor immunity in mice. J Interferon Cytokine Res 17: 37-43, 1997. (Pubitemid 27076280)
20. Bohm W, Thoma S, Leithauser F, Moller P, Schirmbeck R and Reimann J: T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas. J Immunol 161: 897-908, 1998. (Pubitemid 28323555)
21. Taub DD, Sayers TJ, Carter CR and Ortaldo JR: Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. J Immunol 155: 3877-3888, 1995.
22. Maghazachi AA, Skalhegg BS, Rolstad B and Al-Aoukaty A: Interferon-inducible protein-10 and lymphotactin induce the chemotaxis and mobilization of intracellular calcium in natural killer cells through pertussis toxin-sensitive and -insensitive heterotrimeric G-proteins. FASEB J 11: 765-774, 1997. (Pubitemid 27349561)
23. Trinchieri G: Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 70: 83-243, 1998.
24. Dinarello P, Di Carlo E, Musiani P, Meroni PL, Caselli G, Ruggiero P and Boraschi D: IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci USA 100: 14181-14186, 2003. (Pubitemid 37499211)
25. Smyth MJ, Street SE and Trapani JA: Cutting edge: granzymes A and B are not essential for perforin-mediated tumor rejection. J Immunol 171: 515-518, 2003. (Pubitemid 36871353)
26. Raja SM, Wang B, Dantuluri M, Desai UR, Demeler B, Spiegel K, Metkar SS and Froelich CJ: Cytotoxic cell granule-mediated apoptosis. Characterization of the macromolecular complex of granzyme B with serglycin. J Biol Chem 277: 49523-49530, 2002. (Pubitemid 36014390)
27. De Cicco KL, Tanaka T, Andreola F and De Luca LM: The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARAγ pathway. Carcinogenesis 25: 1805-1812, 2004. (Pubitemid 39405898)
28. Fogler WE, Volker K, Watanabe M, Wigginton JM, Roessler P, Brunda MJ, Ortaldo JR and Wiltrout RH: Recruitment of hepatic NK cells by IL-12 is dependent on IFN-γ and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas. J Immunol 161: 6014-6021, 1998. (Pubitemid 28535970)
29. Watanabe M, Fenton RG, Wigginton JM, McCormick KL, Volker KM, Fogler WE, Roessler PG and Wiltrout RH: Intradermal delivery of IL-12 naked DNA induces systemic NK cell activation and Th1 response in vivo that is independent of endogenous IL-12 production. J Immunol 163: 1943-1950, 1999. (Pubitemid 29382196)
30. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ and Schreiber RD: IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111, 2001. (Pubitemid 32391043)
31. Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, Streetly M and Dalgleish AG: Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22: 3269-3276, 2004. (Pubitemid 41103682)
32. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF and Gately MK: Antitumor and anti-metastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 1223-1230, 1993. (Pubitemid 23277355)
33. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD and Storkus WJ: Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 153: 1697-1706, 1994. (Pubitemid 24251114)
34. Okumura H, Tsutsui H, Komatsu T, et al : Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378: 88-91, 1995.
35. Nakahira M, Ahn HJ, Park WR, Gao P, Tomura M, Park CS, Hamaoka T, Ohta T, Kurimoto M and Fujiwara H: Synergy of IL-12 and IL-18 for IFN-γ gene expression: IL-12-induced STAT4 contributes to IFN-γ promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol 168: 1146-1153, 2002. (Pubitemid 34094479)
36. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, Akira S and Nakanishi K: IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J Immunol 161: 3400-3407, 1998.
37. Papadakis KA, Prehn JL, Landers C, Han Q, Luo X, Cha SC, Wei P and Targan SR: TL1A synergizes with IL-12 and IL-18 to enhance IFNγ production in human T cells and NK cells. J Immunol 172: 7002-7007, 2004. (Pubitemid 38669141)
38. Lee RK, Spielman J, Zhao DY, Olsen KJ and Podack ER: Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J Immunol 157: 1919-1925, 1996. (Pubitemid 126449664)
39. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM and Hengartner H: Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369: 31-37, 1994. (Pubitemid 24144352)